VERA VERA THERAPEUTICS INC

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the TD Cowen Immunology & Inflammation Summit, which is taking place virtually from November 12-13, 2025. The management team will also participate in one-on-one investor meetings.

Presentation Details:

Date: Thursday, November 13, 2025

Time: 1:30pm ET

Webcast:

A replay of the event will be available for 90 days and can be accessed by visiting the “” section of the Vera Therapeutics website.

About Vera Therapeutics

Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both BAFF and APRIL, which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell–mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868. For more information, please visit .

For more information, please contact:

Investor Contact:

Joyce Allaire

LifeSci Advisors

212-915-2569

Media Contact:

Debra Charlesworth

Vera Therapeutics

415-854-8051



EN
10/11/2025

Underlying

VERAVERA THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on VERA THERAPEUTICS INC

 PRESS RELEASE
Free
VERA VERA THERAPEUTI...

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflamma...

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the TD Cowen Immunology & Inflammation Summit, which is taking place virtually from November 12-13, 2025. The management team will also participate in one-on-one investor meetings. Presentati...

5h / 32m 1 EN
 PRESS RELEASE
Free
VERA VERA THERAPEUTI...

Vera Therapeutics Submits Biologics License Application to U.S. FDA th...

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from baseline and 42% reduction vs placebo at week 36 (p

November 7, 2025 1 EN
 PRESS RELEASE
Free
VERA VERA THERAPEUTI...

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rul...

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 79,050 shares of Class A common stock and restricted stock units (RSUs) underlying 39,915 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The ...

November 7, 2025 1 EN
 PRESS RELEASE
Free
VERA VERA THERAPEUTI...

Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept...

Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p

November 6, 2025 1 EN
 PRESS RELEASE
Free
VERA VERA THERAPEUTI...

Vera Therapeutics Provides Business Update and Reports Third Quarter 2...

Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN) Kidney Week 2025Biologics License Application (BLA) submission through the Accelerated Approval Program for atacicept for the treatment of IgAN to U.S. FDA expected in Q4; potential U.S. commercial launch of atacicept in 2026Actively enrolling patients in the PIONEER, atacicept monthly dose range f...

November 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch